Kailera Therapeutics, Inc. (KLRA) Key Statistics & Metrics
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
- Shares outstanding
- —
- Float
- —
- Free float
- —
- EPS (TTM)
- —
KLRA stock: frequently asked questions
What is KLRA's ST Score?
Kailera Therapeutics, Inc. (KLRA) has an ST Score of 64.3 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is KLRA a buy, hold, or sell?
Our ST Score grades it B (64.3/100). The ST Score is a data-driven signal, not a recommendation.
What are KLRA's factor grades?
Valuation A, Profitability B+, Financial Strength A, Momentum D, Growth C-, Forecast A.
What is KLRA's valuation grade?
Kailera Therapeutics, Inc. (KLRA) earns a valuation grade of A, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is KLRA's growth grade?
Kailera Therapeutics, Inc. (KLRA) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is KLRA's profitability grade?
Kailera Therapeutics, Inc. (KLRA) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is KLRA's financial strength grade?
Kailera Therapeutics, Inc. (KLRA) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for KLRA?
The average analyst price target for Kailera Therapeutics, Inc. (KLRA) is $42.00, which is +225.8% versus the recent price of $12.89.